Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash ...
Revolution Medicines shows RAS drug optimism with phase 3 catalysts, early-stage valuation, buyout chatter, and competition ...
Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately ...
AHA respectfully requests that you consider the following issues before making your final payment update recommendations at the January Medicare Payment Advisory Commission (MedPAC) meeting.
Camurus has now become cash flow positive, with the ability to fund future projects on its own, which to us makes it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback